Azithromycin
Azithromycin is a macrolide antibiotic useful for the treatment of a number of bacterial infections.
Product Specifications
CAS Number
[83905-01-5]
Product Name Alternative
CP 62993
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Autophagy; Bacterial; Parasite
Type
Reference compound
Related Pathways
Anti-infection; Autophagy
Applications
COVID-19-anti-virus
Field of Research
Infection; Cancer
Assay Protocol
https://www.medchemexpress.com/Azithromycin.html
Purity
98.0
Solubility
DMSO : ≥ 100 mg/mL
Smiles
C[C@@H]([C@@H]([C@@](C(O[C@@H]([C@@](C)(O)[C@@H]1O)CC)=O)([H])C)O[C@@](O[C@@H](C)[C@@H]2O)([H])C[C@@]2(C)OC)[C@H]([C@](O)(C[C@H](CN([C@@H]1C)C)C)C)O[C@@](O[C@H](C)C[C@@H]3N(C)C)([H])[C@@H]3O
Molecular Formula
C38H72N2O12
Molecular Weight
748.98
Precautions
H302, H315, H319, H335
References & Citations
[1]Menzel M, et al. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017 Mar 18.|[2]Vandooren J, et al. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. PLoS One. 2017 Apr 3;12 (4) :e0174853.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
Macrolide
Citation 01
ACS Chem Biol. 2022 Jan 21;17 (1) :39-53.|ACS Infect Dis. 2024 Apr 12;10 (4) :1327-1338.|ACS Omega. 2022 Mar 3;7 (10) :9004-9014.|Acta Pharm Sin B. 2021 Sep;11 (9) :2850-2858.|Adv Sci (Weinh) . 2020 Jul 21;7 (17) :2001374.|Bioact Mater. 2025 Jun 5:52:73-91.|Biochem Biophys Res Commun. 2020 Feb 19;522 (4) :862-868.|Biochem Pharmacol. 2021 Nov:193:114793.|bioRxiv. 2021 Jan 19.|bioRxiv. 2024 Apr 4.|bioRxiv. 2024 May 10.|bioRxiv. 2025 Jun 11.|Cell Rep. 2023 Dec 12;42 (12) :113563.|COVID. 2021, 1 (1), 263-275.|Diabetes Metab Syndr Obes. 2025 Aug 5:18:2681-2694.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.|Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep.|Immunobiology. 2025 Nov;230 (6) :153136.|Immunol Invest. 2025 Jan 9:1-13.|Invest Ophthalmol Vis Sci. 2021 Feb 1;62 (2) :33.|iScience. 2022 Jan 5;25 (2) :103731.|Journal of Pharmaceutical Research International. 33 (47B) : 274-279, 2021.|Katedra farmakologie a toxikologie. 2020 Jul.|Microbiol Spectr. 2025 Aug 29:e0059025.|Microbiol Spectr. 2025 May 19:e0307424.|Microbiol Spectr. 2025 Oct 15:e0122125.|mLife. 2025 Apr 15;4 (2) :155-168.|Nano Today. 2025 Apr.|Patent. US20200101105A1.|Pathogens. 2024 Nov 15;13 (11) :1003.|Pathogens. 2025 Mar 21;14 (4) :302.|PLoS Pathog. 2024 Nov 5;20 (11) :e1012614.|Res Sq. 2025 Apr 16.|Research Square Preprint. 2022 Jun.|Theranostics. 2022 Jan 1;12 (3) :1187-1203.|Vet Microbiol. 2025 Jun 4:307:110582.|Viruses. 2019 Nov 15;11 (11) :1064.|Viruses. 2020 Jun 10;12 (6) :628.|Water. 2025 Jun 6.|Mol Ther. 2022 Jun 1;30 (6) :2224-2241.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
32-10635-500 500 µg
Recombinant Human Tumor protein p53-inducible nuclear protein 1 (C-His)
Ask
View Details 
